Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
| Autor: | Geoffroy Gagliardi, Roberto Ceravolo, Herman Depypere, Bruno Dubois, Fanny Mochel, Christiane Metzinger, George L. W. Perry, Marine Sole, Massimo S. Fiandaca, Amira Saidi, E. Cavedo, Patrizia Andrea Chiesa, Thiebaud de Schotten M, Juan I. Castrillo, Jean Lorenceau, Jeffrey L. Cummings, Craig W. Ritchie, Ubaldo Bonuccelli, Francesco Cacciola, Arun L.W. Bokde, F. Lamari, Keith L. Black, Marion Haberkamp, Jean-Christophe Corvol, Ann De Vos, Maya Koronyo-Hamaoui, Filippo Sean Giorgi, Todd Langevin, H. Hampel, Richard Frank, Stéphane Epelbaum, Mohmed Surtee, Remy Genthon, Nadjia Younsi, Olaf Sporns, Harald Hampel, Marion Dubois, Filippo Baldacci, Lindsay A. Welikovitch, Karl Broich, Stéphane Lehéricy, Henrik Zetterberg, M.O. Habert, Manuela Graziani, Janet Woodcock, S. Lista, Aurélie Kas, Lon S. Schneider, Katia Andrade, Robert Nisticò, Simone Rossi, Foudil Lamari, Howard J. Federoff, Francis Nyasse, Enrica Cavedo, Lisi Flores Aguilar, Erfan Younesi, M.C. Potier, Seung Hyun Kim, Karl Herholz, Nadia Boukerrou, Lucile Megret, Catherine Poisson, Claudio Babiloni, A.C. Cuello, Dalila Mango, Antonio Melo dos Santos, Norbert Benda, Marcel Levy, A. Vergallo, Patrizia A. Chiesa, Sid E. O'Bryant, Marie Revillon, Nicola Toschi, Hugo Geerts, Maria Teresa Ferretti, Mark Mapstone, Kaj Blennow, Eugeen Vanmechelen, Simone Lista, Marie-Odile Habert, Marie-Claude Potier, Eric Karran, Nicolas Villain, Laurie Boukadida, Emiliano Santarnecchi, Yosef Koronyo, Olivier Colliot, Habib Benali, Hugo Bertin, Valentina Escott-Price, Andrea Duggento, Steven Verdooner, Andrea Vergallo, Christian Neri, Joel Bonheur, Francesco Garaci, Hovagim Bakardjian, Marion Houot |
|---|---|
| Přispěvatelé: | Alzheimer Precision Medicine [CHU Pitié-Salpétriêre] (GRC 21 AMP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Adaptation Biologique et Vieillissement = Biological Adaptation and Ageing (B2A), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Apolipoprotein E Oncology Epidemiology [SDV]Life Sciences [q-bio] Simoa immunoassay Disease Cohort Studies Classification and regression trees (CART) Cognition 0302 clinical medicine medicine.diagnostic_test Health Policy Amyloidosis Settore FIS/07 Brain Alzheimer's disease 3. Good health Psychiatry and Mental health Positron emission tomography Cohort Female Amyloid PET Machine learning Plasma amyloid β Subjective memory complainers medicine.medical_specialty 03 medical and health sciences Cellular and Molecular Neuroscience Developmental Neuroscience Alzheimer Disease Memory Internal medicine medicine Humans Aged Amyloid beta-Peptides Receiver operating characteristic business.industry Clinical study design medicine.disease Peptide Fragments Clinical trial Cerebral Amyloid Angiopathy 030104 developmental biology Positron-Emission Tomography Neurology (clinical) Geriatrics and Gerontology business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Alzheimer's and Dementia Alzheimer's and Dementia, Elsevier, 2019, 15, pp.764-775. ⟨10.1016/j.jalz.2019.03.009⟩ |
| ISSN: | 1552-5260 |
| Popis: | Introduction Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. Methods We investigated whether plasma concentrations of the Aβ 1–40 /Aβ 1–42 ratio, assessed using the single-molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large-scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis-driven investigation followed by a no-a-priori hypothesis study using machine learning. Results The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ 1–40 /Aβ 1–42 ratio. The accuracy is not affected by the apolipoprotein E ( APOE ) e4 allele, sex, or age. Discussion Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ 1–40 /Aβ 1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|